Alkermes (ALKS) Projected to Release Quarterly Earnings on Wednesday

Key Points

• Alkermes is expected to report Q3 2026 results before market open on October 28, with analysts forecasting a loss of $0.0809 per share and revenue of $463.61 million.
• The stock recently traded at $44.11, while analysts maintain a consensus “Moderate Buy” rating and an average price target of $54.47.
• Insiders have sold 76,150 shares worth approximately $3.75 million over the past three months, including transactions by senior executives conducted under pre-arranged Rule 10b5-1 plans.

Alkermes (NASDAQ:ALKS - Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of ($0.0809) per share and revenue of $463.61 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Alkermes Trading Up 2.7%

NASDAQ:ALKS opened at $44.11 on Wednesday. The stock has a market cap of $7.40 billion, a price-to-earnings ratio of 99.93 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82. The company's 50 day moving average price is $44.78 and its 200-day moving average price is $43.83. Alkermes has a 52 week low of $27.00 and a 52 week high of $55.67.

Insider Transactions at Alkermes

In other news, SVP Christian Nichols sold 7,576 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $49.23, for a total value of $372,966.48. Following the transaction, the senior vice president owned 102,193 shares in the company, valued at $5,030,961.39. This represents a 6.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig Hopkinson sold 9,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $48.58, for a total transaction of $437,220.00. Following the completion of the transaction, the executive vice president owned 69,389 shares in the company, valued at $3,370,917.62. This trade represents a 11.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 76,150 shares of company stock valued at $3,752,181. Company insiders own 4.59% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. JPMorgan Chase & Co. lifted their target price on Alkermes from $60.00 to $61.00 and gave the stock a "neutral" rating in a report on Wednesday, July 29th. Mizuho raised Alkermes to a "strong-buy" rating in a research report on Wednesday, September 16th. Wells Fargo & Company lifted their price objective on Alkermes from $44.00 to $65.00 and gave the stock an "overweight" rating in a report on Monday, June 29th. Needham & Company LLC reissued a "buy" rating and issued a $62.00 target price on shares of Alkermes in a research report on Monday, September 21st. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $50.00 target price on shares of Alkermes in a research report on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $54.47.

Alkermes Company Profile

Alkermes plc NASDAQ: ALKS is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company's marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.